NeuroSense (NRSN) says PrimeC reduces Alzheimer’s disease biomarkers

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. filed a Form 6-K to share new clinical information about its drug candidate PrimeC. The company reports, via an attached press release dated October 6, 2025, that PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers, which are biological signals linked to Alzheimer’s disease activity. The press release describing these results is furnished as Exhibit 99.1 to this report.

Insights

Biotech and clinical-development analyst

NeuroSense highlights statistically significant Alzheimer’s biomarker reductions from PrimeC.

NeuroSense Therapeutics uses this Form 6-K to circulate a press release stating that its drug candidate PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers. Biomarkers are measurable indicators in patients’ bodies that can reflect disease presence or progression, so changes here can be an early sign that a treatment is having a biological effect.

The filing does not detail trial phase, patient numbers, or the magnitude of the biomarker changes, only that the reductions reached statistical significance. Without those specifics, the clinical and commercial relevance is difficult to gauge from this document alone, but such a finding is typically an important step in therapy development.

The attached press release, furnished as Exhibit 99.1 and dated October 6, 2025, is the primary source for the scientific details. Subsequent company communications and regulatory filings would be needed to understand how these biomarker results translate into clinical outcomes such as cognition or function in Alzheimer’s disease.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of October 2025

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Explanatory Note

On October 6, 2025, NeuroSense Therapeutics Ltd. issued a press release reporting that its drug candidate PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers. A copy of the press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated October 6, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: October 6, 2025	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

3

FAQ

What did NeuroSense Therapeutics (NRSN) report in its October 2025 Form 6-K?

NeuroSense Therapeutics filed a Form 6-K stating, via an attached press release, that its drug candidate PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers.

Which drug candidate is highlighted in NeuroSense Therapeutics (NRSN) latest Form 6-K?

The filing highlights PrimeC, a drug candidate that the company reports produces statistically significant reductions in Alzheimer’s disease biomarkers.

How did NeuroSense Therapeutics (NRSN) disclose the PrimeC Alzheimer’s biomarker results?

NeuroSense disclosed the PrimeC results through a press release dated October 6, 2025, which is furnished as Exhibit 99.1 to the Form 6-K.

What is Exhibit 99.1 in NeuroSense Therapeutics (NRSN) October 2025 Form 6-K?

Exhibit 99.1 is a press release dated October 6, 2025 in which NeuroSense reports that PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers.

Does the NeuroSense Therapeutics (NRSN) Form 6-K include detailed trial data for PrimeC?

The Form 6-K itself primarily notes that PrimeC produced statistically significant reductions in Alzheimer’s disease biomarkers and furnishes a press release for further details.